Article Information
History
- December 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Myriam Drysdale1,*,†,
- Thor Hautekiet2,†,
- Moushmi Singh1,
- Joris Hautekiet3,‡,
- Linda Ludikhuyze3,
- Vishal Patel1,‡,
- Daniel C Gibbons1,
- Dorothée De Roeck4,
- Kirsten Colpaert5,
- Emily J Lloyd1 and
- Eva Van Braeckel2,6
- 1GSK, Brentford, UK
- 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- 3IQVIA Belux, Zaventem, Belgium
- 4GSK, Wavre, Belgium
- 5Department of Intensive Care, Ghent University Hospital, Ghent, Belgium
- 6Respiratory Infection and Defense Lab, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- ↵*Correspondence: Myriam Drysdale myriam.g.drysdale{at}gsk.com
↵† Myriam Drysdale and Thor Hautekiet contributed equally to the manuscript.
Posted December 18, 2023.
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium
